News & Updates

In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.

A single dose of esketamine appears to enhance the efficacy of oral antidepressants for treating patients with major depressive disorder (MDD) who are experiencing fluctuating symptoms, as reported in a small study.

Antibiotics do little in the absence of bacterial pathogens in the nasopharynx of children with acute sinusitis, according to a study, suggesting that testing for specific bacteria on presentation may help prevent unnecessary antibiotic use.